Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company based in San Diego, California. The company specializes in drug delivery solutions, most notably its proprietary ENHANZE technology, which utilizes a recombinant human enzyme to enable the subcutaneous administration of injectable biologics that are traditionally delivered intravenously. By licensing its technology to global pharmaceutical companies, Halozyme helps reduce treatment times for patients while generating significant royalty revenues from partner products.
In 2025, three single customers each accounted for more than 10% of total revenues: Partner A (41%), Partner B (17%), and Partner C (16%).